Market Overview

According to fortune business insights, the global sepsis diagnostics market size was valued at USD 1,003.95 million in 2025 and is projected to grow from USD 1,099.22 million in 2026 to USD 2,399.34 million by 2034, exhibiting a CAGR of 10.20% during the forecast period. North America dominated the sepsis diagnostics market with a market share of 51.50% in 2025.

Fortune Business Insights™ has deep-dived into these insights in its latest research report, titled “Sepsis Diagnostics Market, 2026-2034.”

The analysis shows that the market is growing due to the rising prevalence of sepsis, a life-threatening condition affecting millions globally. Favorable reimbursement policies, various awareness programs, and strategic initiatives by key players to launch new products with advanced technologies are strongly contributing to the market's expansion.

Major Players Profiled in the Market Report:

• T2 Biosystems, Inc. (U.S.)
• Danaher (U.S.)
• Abbott (U.S.)
• bioMérieux SA (France)
• Thermo Fisher Scientific Inc. (U.S.)
• Luminex Corporation (DiaSorin S.p.A.) (U.S.)
• BD (Becton, Dickinson, and Company) (U.S.)
• Bruker (U.S.)
• Siemens Healthcare GmbH (Germany)

Segments

Reagents & Consumables to Dominate the Market Due to Robust Usage

Based on product type, the market is divided into reagents & consumables and instruments. The reagents & consumables segment is projected to lead the market with a 77.22% share in 2026, driven by their extensive and continuous use in diagnostic procedures.

Microbiology Technology to Lead Owing to Cost-Effectiveness

By technology, the market is categorized into microbiology, molecular diagnostics, immunoassays, and others. The microbiology segment is projected to dominate with a 58.85% share in 2026, as blood cultures and other cost-effective microbial tests are the standard of care in most hospitals.

Automated Method to Hold Largest Share Due to High Efficacy